14,725 Shares in INmune Bio, Inc. (NASDAQ:INMB) Purchased by Jane Street Group LLC

Jane Street Group LLC bought a new stake in INmune Bio, Inc. (NASDAQ:INMBFree Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 14,725 shares of the company’s stock, valued at approximately $79,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of INMB. State Street Corp raised its holdings in shares of INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after purchasing an additional 58,838 shares during the period. CVI Holdings LLC bought a new position in INmune Bio during the second quarter worth about $5,260,000. Rhumbline Advisers purchased a new position in shares of INmune Bio in the second quarter worth about $121,000. Financial Advocates Investment Management raised its position in shares of INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after purchasing an additional 2,000 shares during the period. Finally, Fermata Advisors LLC lifted its stake in shares of INmune Bio by 25.2% during the 3rd quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock valued at $230,000 after buying an additional 8,590 shares in the last quarter. 12.72% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

INMB has been the subject of a number of analyst reports. Raymond James initiated coverage on INmune Bio in a report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target for the company. Alliance Global Partners started coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price for the company.

Read Our Latest Stock Report on INMB

INmune Bio Stock Performance

NASDAQ:INMB opened at $6.28 on Thursday. The firm has a market cap of $139.24 million, a PE ratio of -2.88 and a beta of 1.78. INmune Bio, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $14.74. The business has a 50 day moving average price of $5.12 and a 200-day moving average price of $6.11.

INmune Bio (NASDAQ:INMBGet Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 117.48%. During the same period in the prior year, the company posted ($0.48) EPS. Research analysts predict that INmune Bio, Inc. will post -2.24 EPS for the current year.

INmune Bio Profile

(Free Report)

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Recommended Stories

Want to see what other hedge funds are holding INMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for INmune Bio, Inc. (NASDAQ:INMBFree Report).

Institutional Ownership by Quarter for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.